Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31282971 | 1.00 | CNR1 (1.00) | CNR1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL31282350 | 0.91 | CNR1 (0.82) | CNR1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL17548550 | 0.88 | CNR1 (1.00) | CNR1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL31282921 | 0.88 | CNR1 (0.78) | CNR1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL31282892 | 0.86 | CNR1 (0.76) | CNR1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL31282339 | 0.86 | CNR1 (0.75) | CNR1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL31282574 | 0.85 | CNR1 (0.74) | CNR1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL17548474 | 0.85 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL31282426 | 0.83 | CNR1 (0.70) | CNR1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL31283302 | 0.83 | CNR1 (0.70) | CNR1MEN1MAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486336-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| CN-119136797-A | CB1Ligand conjugated compounds and uses thereof | 阿达尔克斯制药有限公司 | 2024-12-13 | — | — | CN | claimed |
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | claimed |
| WO-2023168296-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | claimed |
| WO-2023064228-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| US-20260115176-A1 | ALLOSTERIC MODULATORS OF CANNABINOID RECEPTORS AND METHODS OF TREATING NEUROPATHIC PAIN | UNIV LELAND STANFORD JUNIOR (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4486336-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024263969-A2 | HETEROARYL COMPOUNDS AS ENDOCANNABINOID SYSTEM MODULATORS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-119136797-A | CB1Ligand conjugated compounds and uses thereof | 阿达尔克斯制药有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024112721-A1 | ALLOSTERIC MODULATORS OF THE μ-OPIOID RECEPTOR AND CANNABINOID RECEPTOR 1 | CZ BIOHUB SF, LLC (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-117717546-A | Application of indole derivatives in preparation of medicines for preventing and/or treating pain | 四川大学华西医院 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023064228-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230047251-A1 | ALLOSTERIC MODULATORS OF CANNABINOID RECEPTORS AND METHODS OF TREATING NEUROPATHIC PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | disclosed |
| US-10377711-B2 | Cannabinoid type 1 receptor modulators | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2019-08-13 | — | — | US | disclosed |
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2018-05-03 | — | — | US | disclosed |
| WO-2016029310-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115176-A1 | ALLOSTERIC MODULATORS OF CANNABINOID RECEPTORS AND METHODS OF TREATING NEUROPATHIC PAIN | CNR1, CNR2, OPRL1 | CNR1 1/4885MEN1 4792/4885MAPT 3434/4885 |
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | CNR2, CNR1, OPRM1 | CNR1 2/4885MEN1 4073/4885MAPT 792/4885 |
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | CNR1 1/4885MEN1 3818/4885MAPT 2186/4885 |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | CNR1 1/4885MEN1 3226/4885MAPT 2523/4885 |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | CNR1 1/4885MEN1 3226/4885MAPT 2523/4885 |
| US-10377711-B2 | Cannabinoid type 1 receptor modulators | CNR1, CNR2, GPR18 | CNR1 1/4885MEN1 3818/4885MAPT 2186/4885 |
| US-20230047251-A1 | ALLOSTERIC MODULATORS OF CANNABINOID RECEPTORS AND METHODS OF TREATING NEUROPATHIC PAIN | CNR1, CNR2, TRPV1 | CNR1 1/4885MEN1 4792/4885MAPT 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.